stockrow
Friday 6 November 2026
Export TXG’s income statement to Excel — free account
10x Genomics
TXG Healthcare Medical Devices
10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.
- Revenue
- +1.12%
- EPS
- +31.8%
- Free cash flow
- −4.61%
Quarter to September 2026, against a year earlier
57.82
0.24
−0.41%
Follow TXG
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
6 | 7 | 3 | 3 | 6 | 3 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
3.99 | 3.32 | 16.01 | 10.30 | 48.88 | 43.23 | 10.08 | — | — |
P/S ratio |
3.17 | 2.83 | 10.28 | 7.79 | 33.51 | 47.93 | 29.78 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
1.63 | 0.28 | 0.47 | 2.65 | 5.26 | 2.02 | 5.15 | (7.91) | — |
P/FCF ratio |
15.76 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
(3.23) | (3.69) | (3.52) | (2.85) | (1.90) | (3.91) | (1.74) | — | — |
P/Operating CF |
49.90 | (256.33) | 246.99 | 293.13 | 2,831.60 | (110.03) | 1,092.84 | 201.13 | 0.00 |
P/B ratio |
2.56 | 2.44 | 8.59 | 4.99 | 20.11 | 19.38 | 17.43 | 0.00 | 0.00 |
Price to Tangible BV |
2.79 | 2.51 | 8.84 | 5.17 | 20.87 | 19.98 | 18.39 | 0.00 | 0.00 |
EV/Sales |
2.40 | 2.24 | 9.70 | 7.01 | 32.37 | 45.75 | 28.17 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
11.33 | 204.98 | (395.02) | (107.71) | (742.93) | (62.75) | 200.06 | (10.66) | 0.00 |
EV/FCF |
11.93 | (203.00) | (92.75) | (21.90) | (129.46) | (53.71) | (853.68) | (7.40) | 0.00 |
Quick Ratio |
3.95 | 4.10 | 3.96 | 4.10 | 6.11 | 6.19 | 7.26 | 2.88 | 2.77 |
Current Ratio |
4.46 | 4.97 | 4.69 | 4.85 | 6.77 | 6.56 | 7.63 | 3.28 | 3.09 |
Net Debt/EBITDA |
30.49 | 2.61 | 1.75 | 3.21 | 24.52 | 1.32 | 16.78 | 0.33 | (8.60) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 4.90% | 23.87% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 1.28 | 0.00 |
Asset Turnover |
0.66 | 0.65 | 0.62 | 0.50 | 0.50 | 0.39 | 0.67 | 2.35 | 0.71 |
Operating CF/Net income |
(3.12) | (0.04) | 0.06 | 0.20 | 0.37 | 0.40 | (1.11) | 0.68 | 0.57 |
Capex/Depreciation |
(0.14) | (0.31) | (1.14) | (3.99) | (3.58) | (2.02) | (6.05) | (1.72) | (0.87) |
Interest Coverage |
— | (48,639.75) | (8,040.27) | (352.82) | (60.34) | (317.56) | (9.93) | (45.98) | (22.66) |
| (5.78%) | (25.17%) | (32.98%) | (20.45%) | (7.48%) | (93.64%) | (31.24%) | 67.56% | 11.27% | |
| (4.44%) | (19.39%) | (25.59%) | (16.21%) | (5.98%) | (70.70%) | (8.56%) | (180.97%) | (18.76%) | |
ROIC |
(13.97%) | (38.39%) | (47.06%) | (28.13%) | (14.26%) | (566.77%) | (74.54%) | 0.00% | (9.49%) |
Return on Tangible Assets |
(5.75%) | (25.39%) | (34.08%) | (20.92%) | (7.22%) | (74.44%) | (6.70%) | (132.33%) | (35.40%) |
Average Days of Receivables |
46.84 | 52.87 | 67.74 | 73.66 | 63.44 | 62.54 | 49.54 | 70.07 | 66.75 |
Research and Development Expense of Revenue |
37.12% | 43.34% | 43.69% | 51.45% | 43.17% | 41.28% | 33.79% | 32.49% | 45.25% |
Selling, General and Administrative Expense of Revenue |
49.18% | 56.38% | 55.49% | 57.76% | 52.51% | 67.70% | 53.21% | 60.10% | 65.75% |
Intangible Assets out of Total Assets |
0.06 | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | 0.04 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
16.97% | 23.04% | 26.98% | 26.50% | 19.56% | 16.27% | 5.42% | 1.82% | 2.34% |
Graham Net Nets |
0.22 | 0.22 | 0.06 | 0.10 | 0.03 | 0.04 | 0.04 | 0.13 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(2.15%) | (10.58%) | (4.00%) | (4.16%) | (0.35%) | (3.64%) | (1.76%) | (2.62%) | (1.74%) |
Free Cash Flow Yield |
6.35% | (0.39%) | (1.02%) | (4.11%) | (0.75%) | (1.78%) | (0.11%) | (12.94%) | 0.00% |
Revenue per Share |
5.15 | 5.07 | 5.28 | 4.54 | 4.44 | 2.95 | 6.29 | 10.93 | 6.13 |
Operating CF per Share |
1.09 | 0.06 | (0.13) | (0.30) | (0.19) | (2.15) | 0.89 | (5.71) | (0.92) |
Capex per Share |
(0.05) | (0.11) | (0.42) | (1.16) | (0.92) | (0.38) | (1.09) | (0.50) | (0.32) |
Free Cash Flow per Share |
1.04 | (0.06) | (0.55) | (1.45) | (1.11) | (2.53) | (0.21) | (6.21) | (1.25) |
Cash per Share |
4.20 | 3.27 | 3.32 | 3.80 | 5.33 | 6.72 | 10.85 | 4.86 | 4.14 |
Shareholders Equity per Share |
6.38 | 5.90 | 6.32 | 7.08 | 7.41 | 7.31 | 10.75 | 1.74 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
6.38 | 5.90 | 6.32 | 7.08 | 7.41 | 7.31 | 10.75 | 1.74 | 0.00 |
Free Cash Flow |
130.12 | (6.73) | (64.72) | (165.27) | (122.65) | (256.29) | (8.14) | (83.12) | (14.45) |
Working Capital |
531.00 | 466.75 | 468.86 | 504.08 | 637.23 | 656.24 | 417.79 | 73.87 | 46.00 |
Capital Expenditures |
(5.93) | (13.39) | (49.52) | (131.66) | (101.28) | (38.39) | (42.77) | (6.71) | (3.76) |
Net Current Asset Value |
439.41 | 375.89 | 371.92 | 411.80 | 546.33 | 584.10 | 295.00 | 5.18 | 68.00 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.02 | 0.08 | 0.26 | 0.21 | 0.13 | 0.17 | 0.05 | 0.05 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.19 | 0.17 | 0.16 | 0.11 | 0.17 | 0.26 | 0.14 | 0.35 | 0.62 |
Cash ROIC |
9.86% | (0.61%) | (5.73%) | (13.35%) | (8.72%) | (18.06%) | (0.93%) | (70.43%) | (6.66%) |
Accounts Receivable Turnover |
7.52 | 6.01 | 5.65 | 5.45 | 7.19 | 7.07 | 8.00 | 7.12 | 3.47 |
Accounts Payable Turnover |
15.52 | 13.71 | 11.22 | 6.18 | 6.72 | 6.59 | 5.59 | 4.16 | 1.51 |
Inventory Turnover |
2.85 | 2.50 | 2.70 | 1.70 | 1.65 | 2.59 | 5.12 | 4.22 | 1.51 |
Average Days of Payables |
23.36 | 24.00 | 27.43 | 65.49 | 85.48 | 29.40 | 77.91 | 111.97 | 172.82 |
Days of Inventory on Hand |
103.37 | 154.53 | 128.47 | 247.49 | 295.42 | 187.03 | 91.32 | 109.14 | 172.82 |
Average Receivables |
85.48 | 101.65 | 109.52 | 94.73 | 68.23 | 42.29 | 30.73 | 20.54 | 20.50 |
Average Payables |
12.82 | 14.32 | 18.67 | 19.48 | 11.03 | 8.87 | 10.91 | 6.90 | 7.00 |
Average Inventory |
69.72 | 78.41 | 77.67 | 70.80 | 44.96 | 22.61 | 11.92 | 6.79 | 7.00 |
Average Assets |
980.00 | 941.89 | 997.06 | 1,023.90 | 974.08 | 767.63 | 365.12 | 62.16 | 100.00 |
Average Common Equity |
753.23 | 725.59 | 773.39 | 811.66 | 778.32 | 579.58 | 100.05 | (166.49) | (166.50) |
Columns are period end dates · fundamentals updated 6 Nov 2026